Abeona Therapeutics (ABEO) Net Cash Flow (2011 - 2026)

Abeona Therapeutics' Net Cash Flow history runs 16 years deep, the most recent figure standing at -$17.1 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 129.93% year-over-year to -$17.1 million in Q1 2026; TTM through Mar 2026 was $45.1 million, a 2880.52% increase from a year earlier, with the FY2025 full-year figure at $54.7 million, up 516.19% from the prior year.
• Net Cash Flow eased to -$17.1 million in Q1 2026 per ABEO's latest filing, from -$4.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $147.6 million in Q2 2025 and bottomed at -$80.7 million in Q3 2025.
• The 5-year median for Net Cash Flow is -$1.5 million (2023), against an average of $1.5 million.
• Biggest YoY gain for Net Cash Flow was 991.78% in 2024; the steepest drop was 1135.96% in 2024.
• Year by year, Net Cash Flow stood at $3.5 million in 2022, then soared by 180.17% to $9.8 million in 2023, then fell by 21.82% to $7.6 million in 2024, then slumped by 162.7% to -$4.8 million in 2025, then plunged by 256.59% to -$17.1 million in 2026.
• Per Business Quant, the three latest ABEO Net Cash Flow figures stand at -$17.1 million (Q1 2026), -$4.8 million (Q4 2025), and -$80.7 million (Q3 2025).